Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study
Main finding · Anaphylaxis IR per 10,000 person-yearsResult — go to the resultUnadjusted incidence rate ratio 0.24 95% CI 0.01–1.35Authors' conclusion
Anaphylaxis is rare with GLP-1 RAs. Lixisenatide is unlikely to confer higher risk of anaphylaxis than other GLP-1 RAs.
Study context
- Population
- Adult (≥18 years) new users of a GLP-1 RA with T2D and ≥6 months database enrollment before initiation, three US claims databases (2017–2021)
- Participants
- 696,089 participants456,612 person-years
- Exposure
- Lixisenatide vs other GLP-1 RAs
- Outcome
- First anaphylaxis event during follow-up (validated algorithm); IR per 10,000 person-years
Methodological detailsthree US claims databases, new-user design, post hoc IRR analysis
- Three US claims databases
- New-user design
- Post hoc IRR analysis
Main finding
Anaphylaxis IR per 10,000 person-years
Unadjusted incidence rate ratio
0.24
95% CI 0.01–1.35
By group
Lixisenatidevs Pooled other GLP-1 RAs
unadjusted IRR 0.24 (95% CI 0.01–1.35)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study. Diabetes Care. Published 16 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →